This FDA-approved EZH2 inhibitor has shown efficacy in advanced epithelioid sarcoma and follicular lymphoma and has demonstrated anti-tumor activity in HCC by inhibiting CD13 and β-catenin expression, thus curtailing tumor development and progression [178]. Here, EZH2 is linked to neoplasm.